search
Back to results

Gastric Gluten-Degradation Activity of PvP001

Primary Purpose

Digestive System Disease

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Low-dose PvP001
Medium-dose PvP001
High-dose PvP001
Placebo
Sponsored by
Danielle Kim Turgeon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Digestive System Disease

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy volunteers;
  • Able to maintain a gluten-free diet (GFD) for 24 hours prior to each of visits 1-4;
  • Able to abstain from alcohol consumption 72 hours before and 72 hours after each visit;
  • Able to tolerate the placement, presence, and manipulation of an oro-gastro-duodenal (OGD) tube;
  • Women of child-bearing potential and men whose partners are women of child-bearing potential must be willing to use acceptable birth control for the duration of the study;
  • Able to read and understand English;
  • Able to provide written informed consent

Exclusion Criteria:

  • Any condition or abnormality, current or past, that, in the opinion of the investigator, would compromise the safety of the subject, or would interfere with or complicate study procedures or assessments.
  • No current or recent (within 14 days prior to each study visit, clinical laboratory testing, and ECG) use of over-the-counter or prescription medications via any route of administration, except for oral contraceptives for birth control (provided they have been used regularly for at least the past 3 months). Other medications used regularly at stable doses may be acceptable at the discretion of the study doctor.
  • Current symptoms of congestion, upper respiratory tract infection, or acute illness
  • Chronic viral infection or immunodeficiency condition
  • Any female who is pregnant, planning to become pregnant during the study, or breast-feeding
  • History of intolerance, hypersensitivity, or reaction to wheat or other grains, gluten, or any other food or food ingredient (including an additive or preservative) in the study meal;
  • Receipt of an investigational medication within four weeks prior to the screening visit or from the screening visit through the final visit;
  • Alcohol consumption >5 drinks/week or any alcohol consumption within the 72 hours prior to each study exposure visit or a positive breathalyzer test result at any study visit;
  • Illicit or recreational drug use in the past 12 months or positive urine drug screen at the screening visit;
  • History of smoking, nicotine, or tobacco use in the past 12 months;
  • History or high risk of noncompliance with treatment or visits.

Sites / Locations

  • Michigan Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Gluten Exposure Group 1

Gluten Exposure Group 2

Gluten Exposure Group 3

Arm Description

This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.

This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, to the dose of PvP001 and to which visit placebo is given.

This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.

Outcomes

Primary Outcome Measures

Number of treatment emergent adverse events
The number of treatment emergent adverse events at each dosage level
Percentage of treatment emergent adverse events
The percentage of treatment emergent adverse events at each dosage level
Side effects of study drug
Side effects are assessed by the PI using a 5-scale, 9-question Gastrointestinal Symptoms Questionnaire (GSQ) to be self-administered by the subject at 16 time-points throughout the five-visit (including screening) study. Each of the 9 questions will be given a numerical score (0-4 where 0 is none and 4 is very severe) and compared to baseline score and placebo scores any increase of >1 point over the average baseline and placebo score will be considered an AE and graded based on the severity reported.
Efficacy as measured by the lowest dose to degrade highest amount of gluten
The lowest dose of PvP001 that degrades the highest amount of gluten in a standardized study meal

Secondary Outcome Measures

Full Information

First Posted
June 21, 2018
Last Updated
February 10, 2019
Sponsor
Danielle Kim Turgeon
Collaborators
PvP Biologics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03594331
Brief Title
Gastric Gluten-Degradation Activity of PvP001
Official Title
A Phase I, First-in-Human Single Center Study in Healthy Adult Volunteers to Assess the Gastric Gluten-Degradation Activity of PvP001
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Terminated
Why Stopped
Funding stopped
Study Start Date
May 25, 2018 (Actual)
Primary Completion Date
February 6, 2019 (Actual)
Study Completion Date
February 6, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Danielle Kim Turgeon
Collaborators
PvP Biologics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a single blind, dose escalating, placebo-controlled, crossover study of gluten-degrading drug PvP001 administered to healthy volunteers (age 18-64 years). Subjects will be randomized to one of three groups representing different levels of gluten exposure - low, medium, or high - in a single meal. Within each gluten exposure group, increasing doses of PvP001 (or placebo) will be administered.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Digestive System Disease

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
43 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Gluten Exposure Group 1
Arm Type
Experimental
Arm Description
This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
Arm Title
Gluten Exposure Group 2
Arm Type
Experimental
Arm Description
This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, to the dose of PvP001 and to which visit placebo is given.
Arm Title
Gluten Exposure Group 3
Arm Type
Experimental
Arm Description
This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
Intervention Type
Drug
Intervention Name(s)
Low-dose PvP001
Intervention Description
Low-dose PvP001
Intervention Type
Drug
Intervention Name(s)
Medium-dose PvP001
Intervention Description
Medium-dose PvP001
Intervention Type
Drug
Intervention Name(s)
High-dose PvP001
Intervention Description
High-dose PvP001
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
100 mL liquid with no drug
Primary Outcome Measure Information:
Title
Number of treatment emergent adverse events
Description
The number of treatment emergent adverse events at each dosage level
Time Frame
2 weeks from each exposure.
Title
Percentage of treatment emergent adverse events
Description
The percentage of treatment emergent adverse events at each dosage level
Time Frame
2 weeks from each exposure.
Title
Side effects of study drug
Description
Side effects are assessed by the PI using a 5-scale, 9-question Gastrointestinal Symptoms Questionnaire (GSQ) to be self-administered by the subject at 16 time-points throughout the five-visit (including screening) study. Each of the 9 questions will be given a numerical score (0-4 where 0 is none and 4 is very severe) and compared to baseline score and placebo scores any increase of >1 point over the average baseline and placebo score will be considered an AE and graded based on the severity reported.
Time Frame
12 months
Title
Efficacy as measured by the lowest dose to degrade highest amount of gluten
Description
The lowest dose of PvP001 that degrades the highest amount of gluten in a standardized study meal
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy volunteers; Able to maintain a gluten-free diet (GFD) for 24 hours prior to each of visits 1-4; Able to abstain from alcohol consumption 72 hours before and 72 hours after each visit; Able to tolerate the placement, presence, and manipulation of an oro-gastro-duodenal (OGD) tube; Women of child-bearing potential and men whose partners are women of child-bearing potential must be willing to use acceptable birth control for the duration of the study; Able to read and understand English; Able to provide written informed consent Exclusion Criteria: Any condition or abnormality, current or past, that, in the opinion of the investigator, would compromise the safety of the subject, or would interfere with or complicate study procedures or assessments. No current or recent (within 14 days prior to each study visit, clinical laboratory testing, and ECG) use of over-the-counter or prescription medications via any route of administration, except for oral contraceptives for birth control (provided they have been used regularly for at least the past 3 months). Other medications used regularly at stable doses may be acceptable at the discretion of the study doctor. Current symptoms of congestion, upper respiratory tract infection, or acute illness Chronic viral infection or immunodeficiency condition Any female who is pregnant, planning to become pregnant during the study, or breast-feeding History of intolerance, hypersensitivity, or reaction to wheat or other grains, gluten, or any other food or food ingredient (including an additive or preservative) in the study meal; Receipt of an investigational medication within four weeks prior to the screening visit or from the screening visit through the final visit; Alcohol consumption >5 drinks/week or any alcohol consumption within the 72 hours prior to each study exposure visit or a positive breathalyzer test result at any study visit; Illicit or recreational drug use in the past 12 months or positive urine drug screen at the screening visit; History of smoking, nicotine, or tobacco use in the past 12 months; History or high risk of noncompliance with treatment or visits.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Danielle Kim Turgeon, MD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Michigan Medicine
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Gastric Gluten-Degradation Activity of PvP001

We'll reach out to this number within 24 hrs